The local injection of recombinant IL-2 can form rIL-2 depots in melanoma, effectively induce a local immune response, reduce the excessive activation of systemic immune cells, have a highly enhanced therapeutic effect, and significantly reduce the impact of rIL-2 on systemic adverse effects [148]. The gene discussed is IL2; the disease is melanoma.